CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative therapy, SYS6020. This therapy is a BCMA-targeted chimeric antigen receptor (CAR)-T cell treatment designed for systemic lupus erythematosus (SLE), an autoimmune disease.
SYS6020 is distinguished as the world’s first mRNA-lipid nanoparticle (LNP)-based cell therapy to be approved for clinical trials. It is lauded for its high cell viability, high CAR positivity rate, and the absence of oncogenic risks associated with genome integration. Additionally, it is noted for its lower potential side effects, such as cytokine release syndrome (CRS), when compared to traditional CAR-T products.- Flcube.com
